Literature DB >> 7400974

Comparison of the biotransformation and hepatotoxicity of halothane and deuterated halothane.

I G Sipes, A J Gandolfi, L R Pohl, G Krishna, B R Brown.   

Abstract

To investigate the effect of deuterium substitution on the biotransformation and hepatotoxicity of halothane, male, phenobarbital-pretreated rats were exposed for 2 hr to 1% halothane or deuterated halothane (d-halothane) delivered in 14% O2-85% N2. The exposures were performed at mildly hypoxic conditions (14% O2) since it was previously established that the decreased oxygen tension promotes both the reductive metabolism of halothane and halothane-induced liver injury. At the end of anesthesia or at 24 hr, the rats were sarificed so that blood, liver and urine samples could be obtained for measurement of metabolites and assessment of liver damage. Deuterium substitution did not affect the levels of reductive metabolites of halothane (fluoride, CF3CH2Cl and CF2CHCl) nor did it alter the degree of hepatotoxicity as assessed by serum glutamic-pyruvic transaminase levels and morphological examination. The levels of oxidative metabolites (CF3COOH and bromide) were significantly reduced at the end of anesthesia and at 24 hr. It is concluded that halothane-induced hepatotoxicity is initiated by reactive intermediates formed during its reductive metabolism and that cleavage of the C-H bond is not involved in this pathway. The oxidative biotransformation of halothane proceeds by an oxygen insertion reaction at the C-H bond. Thus, the increased stability of the C-D bond explains the reduction in oxidative metabolities observed after exposure to d-halothane.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7400974

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

Review 1.  Halothane and liver damage.

Authors:  D Rosenak; A Halevy; R Orda
Journal:  Postgrad Med J       Date:  1989-03       Impact factor: 2.401

2.  Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase.

Authors:  H Satoh; B M Martin; A H Schulick; D D Christ; J G Kenna; L R Pohl
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

3.  Olfactory cytochrome P-450. Studies with suicide substrates of the haemoprotein.

Authors:  C J Reed; E A Lock; F De Matteis
Journal:  Biochem J       Date:  1988-07-15       Impact factor: 3.857

Review 4.  Drug-induced immunotoxicity.

Authors:  P M Dansette; E Bonierbale; C Minoletti; P H Beaune; D Pessayre; D Mansuy
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Oct-Dec       Impact factor: 2.441

5.  Halothane hepatotoxicity and hepatic free radical metabolism in guinea pigs; the effects of vitamin E.

Authors:  I Durak; T Güven; M Birey; H S Oztürk; O Kurtipek; M Yel; B Dikmen; O Canbolat; M Kavutcu; M Kaçmaz
Journal:  Can J Anaesth       Date:  1996-07       Impact factor: 5.063

Review 6.  Clinical pharmacokinetics of the inhalational anaesthetics.

Authors:  O Dale; B R Brown
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

7.  Localization of halothane-induced antigen in situ by specific anti-halothane metabolite antibodies.

Authors:  A K Hubbard; T P Roth; S Schuman; A J Gandolfi
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

8.  Halothane-induced hepatitis: A forgotten issue in developing countries: Halothane-induced hepatitis.

Authors:  Peiman Habibollahi; Nastaran Mahboobi; Sara Esmaeili; Saeid Safari; Ali Dabbagh; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2011-01       Impact factor: 0.660

Review 9.  Toxicology of chlorofluorocarbon replacements.

Authors:  W Dekant
Journal:  Environ Health Perspect       Date:  1996-03       Impact factor: 9.031

10.  Model studies in cytochrome P-450-mediated toxicity of halogenated compounds: radical processes involving iron porphyrins.

Authors:  D Brault
Journal:  Environ Health Perspect       Date:  1985-12       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.